FDA-authorized profile

QuantX

Quantitative Insights, Inc

QuantX is breast MRI software for the labeled management, analysis, visualization, and decision-support workflow; exact image inputs, outputs, and use remain submission-specific.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
QuantX is breast MRI software for the labeled management, analysis, visualization, and decision-support workflow; exact image inputs, outputs, and use remain submission-specific.
FDA source Exact FDA submission Checked 2026-09-04
Intended users
Qualified radiologists and trained breast-imaging professionals.
FDA source Exact FDA submission Checked 2026-09-04
Care setting and population
Breast MRI workstations and imaging practices using the exact cleared software and compatible source studies.
FDA source Exact FDA submission Checked 2026-09-04
Workflow role
Breast MRI image analysis, visualization, or decision support as an adjunct to physician interpretation.
FDA source Exact FDA submission Checked 2026-09-04
Required input
Supported breast MRI images and release-specific DICOM metadata.
FDA source Exact FDA submission Checked 2026-09-04
Output and human action
Breast MRI analysis, visualization, measurements, or decision-support outputs for professional review.
FDA source Exact FDA submission Checked 2026-09-04
Limitations
Exact MRI sequence, contrast, anatomy, patient population, image quality, and review workflow limits require submission-specific labeling. QuantX is breast MRI software for the labeled management, analysis, visualization, and decision-support workflow; exact image inputs, outputs, and use remain submission-specific.
FDA source Exact FDA submission Checked 2026-09-04

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
DEN170022
FDA source Exact FDA submission Checked 2026-08-31
Modality
MRI
FDA source Exact FDA submission Checked 2026-09-04
Anatomy
Breast
FDA source Exact FDA submission Checked 2026-09-04
Clearance type
De Novo
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2017-07-19
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-authorized
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
Standards-based DICOM/PACS integration was identified in the FDA submission materials; compatibility with a specific PACS, RIS, EHR, or orchestrator requires confirmation.
Public source Exact FDA submission Checked 2026-08-13

Normalized from the prior exact-submission review. Confirm interface versions and local compatibility during technical evaluation.

Deployment and data flow
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.

Security and privacy
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

Public sources reviewed here do not establish the complete exact-release security posture, including identity, audit, encryption, retention, remote access, vulnerability management, backup, or incident response.

Training and support
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13

Training, onboarding, competency, and support commitments are commercial implementation details that require current vendor documentation.

Monitoring and change control
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13

Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.

Workflow role

Breast MRI image analysis, visualization, or decision support as an adjunct to physician interpretation.

exact submission · checked 2026-09-04

This is a submission-anchored intended-use summary, not a local acceptance result.

Input

Supported breast MRI images and release-specific DICOM metadata.

exact submission · checked 2026-09-04

Exact supported inputs and protocol limits must be confirmed from the complete labeling.

Output

Breast MRI analysis, visualization, measurements, or decision-support outputs for professional review.

exact submission · checked 2026-09-04

Output review, editing, and downstream use remain release- and site-specific.

Vendor family context

Current vendor material is product-family context for DEN170022 only; exact release, enabled options, deployment, and local interoperability require confirmation.

product family · checked 2026-09-04

Vendor material is not exact-release evidence unless that linkage is separately proven.

Site validation status

Exact local interfaces, deployment topology, security controls, downtime behavior, and support obligations remain unestablished.

exact submission · checked 2026-09-04

Obtain organization-specific implementation evidence before procurement or clinical use.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
The exact FDA submission DEN170022 is the identity anchor. Its public decision material supports the submission-specific product and intended-use summary recorded here; it does not establish a general product-wide sensitivity or specificity value for this dossier.
FDA source Exact FDA submission Checked 2026-09-04
Reported sensitivity
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No exact submission and version-linked sensitivity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.

Reported specificity
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No exact submission and version-linked specificity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

FDA submission-specific verification and validation evidence for DEN170022

Regulatory verification, validation, and labeling evidence reviewed for exact FDA submission DEN170022. · The labeled population and test materials for exact submission DEN170022; a general clinical study population is not established here.

exact submission · Tested version: QuantX (DEN170022) · Sponsor or vendor study

DEN170022

FDA regulatory evidence is submission-specific but is not independent clinical performance evidence.

A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer.

Candidate peer-reviewed literature record discovered by exact-name or identifier search. · Candidate record population; product and version linkage to DEN170022 was not established.

product family · Tested version: Candidate product-family record; exact FDA submission and product version linkage not established. · Independence not established

35193025

Quarantined candidate evidence: do not treat this record as exact-submission performance evidence without product and version linkage review.

Comparison of Digital Analysis and Artificial Intelligence for Cephalometric Tracing

Candidate clinical-trial registry record discovered by exact-name or identifier search. · Candidate registry population; product and version linkage to DEN170022 was not established.

product family · Tested version: Candidate product-family record; exact FDA submission and product version linkage not established. · Independence not established

NCT07664488

Quarantined candidate evidence: do not treat this record as exact-submission performance evidence without product and version linkage review.

A Single and Multiple Ascending Dose Escalation and Food Effect Study of QX-4533 in Healthy Participants

Candidate clinical-trial registry record discovered by exact-name or identifier search. · Candidate registry population; product and version linkage to DEN170022 was not established.

product family · Tested version: Candidate product-family record; exact FDA submission and product version linkage not established. · Independence not established

NCT07678463

Quarantined candidate evidence: do not treat this record as exact-submission performance evidence without product and version linkage review.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.

Reimbursement and coding
Not applicable
Not applicable Not applicable Checked 2026-09-04

CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-04Last searched
27Fields reviewed
12Source classes checked
1Unreviewed PubMed leads
2Unreviewed trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA identity, indication, modality, anatomy, workflow, and limitations were reviewed using the submission as the identity anchor. Current vendor material is product-family context only. PubMed and ClinicalTrials.gov candidates remain quarantined as product-family evidence because exact submission and version linkage was not established. CMS and openFDA index context was checked. Pricing, security, deployment, reimbursement, contracted services, enabled options, and local interoperability remain unknown unless separately evidenced. Automated exact-name discovery found 1 PubMed and 2 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-04.

Alternatives

Related tools to compare

FDA-cleared K211431

breastscape v1.0

Olea Medical

FDA product code QIH identifies this device class as Automated Radiological Image Processing Software. To provide automated radiological image processing and analysis tools....

Modality
MRI
Anatomy
Breast
Decision
2021-08-02
FDA-cleared K231130

TumorSight Viz

SimBioSys, Inc.

TumorSight Viz analyzes dynamic contrast-enhanced breast MRI for visualization and analysis of biopsy-proven early-stage or locally advanced breast cancer, including registration,...

Modality
MRI
Anatomy
Breast; early-stage or locally advanced breast cancer
Decision
2023-12-26
FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained...

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K261273

Neurophet AQUA

Neurophet., Inc.

Neurophet AQUA is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from a set of MR images; volumetric...

Modality
MRI
Anatomy
Brain; segmentable structures and lesions
Decision
2026-05-15